Immune effects of α-interferon in chronic liver disease

Marion Peters; D. M. Walling; Jeanne Waggoner; Mark I. Avigan; Maria Sjogren; J. H. Hoofnagle

doi:10.1016/S0168-8278(86)80133-7

Immune effects of α-interferon in chronic liver disease

Marion Peters^*, D. M. Walling, Jeanne Waggoner, Mark I. Avigan, Maria Sjogren, J. H. Hoofnagle

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The effect of prolonged α-interferon therapy on immune function was studied in patients with chronic type B hepatitis. These patients with chronic type B hepatitis have been shown to have a defect in their in vitro response to human recombinant α-interferon. This defect consists of a failure to augment pokeweed mitogen-stimulated immunoglobulin production at low concentrations of interferon and an increased susceptibility to the suppressive effects of interferon. After 2 weeks therapy with interferon, immunoglobulin production was further suppressed. However, after 4 months of therapy with interferon, pokeweed mitogen-stimulated immunoglobulin production partially returned towards the pretreatment values. Antibody to hepatitis B core antigen was less affected by interferon therapy. This altered response to interferon was not specific as it was seen in some patients with other forms of liver disease. The suppression of B cell differentiation appears to be separate from its antiviral and anti-proliferative effects.

Original language	English
Pages (from-to)	S283-S289
Journal	Journal of Hepatology
Volume	3
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/S0168-8278(86)80133-7
State	Published - 1986
Externally published	Yes

Access to Document

10.1016/S0168-8278(86)80133-7

Cite this

@article{882bba8905144350a6b082cce75ae1a2,

title = "Immune effects of α-interferon in chronic liver disease",

abstract = "The effect of prolonged α-interferon therapy on immune function was studied in patients with chronic type B hepatitis. These patients with chronic type B hepatitis have been shown to have a defect in their in vitro response to human recombinant α-interferon. This defect consists of a failure to augment pokeweed mitogen-stimulated immunoglobulin production at low concentrations of interferon and an increased susceptibility to the suppressive effects of interferon. After 2 weeks therapy with interferon, immunoglobulin production was further suppressed. However, after 4 months of therapy with interferon, pokeweed mitogen-stimulated immunoglobulin production partially returned towards the pretreatment values. Antibody to hepatitis B core antigen was less affected by interferon therapy. This altered response to interferon was not specific as it was seen in some patients with other forms of liver disease. The suppression of B cell differentiation appears to be separate from its antiviral and anti-proliferative effects.",

author = "Marion Peters and Walling, {D. M.} and Jeanne Waggoner and Avigan, {Mark I.} and Maria Sjogren and Hoofnagle, {J. H.}",

note = "Funding Information: Liver Diseases Section, Digestive Diseases Branch, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 and Walter Reed Army Institute of Research, Washington, DC (U.S.A.)",

year = "1986",

doi = "10.1016/S0168-8278(86)80133-7",

language = "English",

volume = "3",

pages = "S283--S289",

journal = "Journal of Hepatology",

issn = "0168-8278",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Immune effects of α-interferon in chronic liver disease

AU - Peters, Marion

AU - Walling, D. M.

AU - Waggoner, Jeanne

AU - Avigan, Mark I.

AU - Sjogren, Maria

AU - Hoofnagle, J. H.

N1 - Funding Information: Liver Diseases Section, Digestive Diseases Branch, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 and Walter Reed Army Institute of Research, Washington, DC (U.S.A.)

PY - 1986

Y1 - 1986

N2 - The effect of prolonged α-interferon therapy on immune function was studied in patients with chronic type B hepatitis. These patients with chronic type B hepatitis have been shown to have a defect in their in vitro response to human recombinant α-interferon. This defect consists of a failure to augment pokeweed mitogen-stimulated immunoglobulin production at low concentrations of interferon and an increased susceptibility to the suppressive effects of interferon. After 2 weeks therapy with interferon, immunoglobulin production was further suppressed. However, after 4 months of therapy with interferon, pokeweed mitogen-stimulated immunoglobulin production partially returned towards the pretreatment values. Antibody to hepatitis B core antigen was less affected by interferon therapy. This altered response to interferon was not specific as it was seen in some patients with other forms of liver disease. The suppression of B cell differentiation appears to be separate from its antiviral and anti-proliferative effects.

AB - The effect of prolonged α-interferon therapy on immune function was studied in patients with chronic type B hepatitis. These patients with chronic type B hepatitis have been shown to have a defect in their in vitro response to human recombinant α-interferon. This defect consists of a failure to augment pokeweed mitogen-stimulated immunoglobulin production at low concentrations of interferon and an increased susceptibility to the suppressive effects of interferon. After 2 weeks therapy with interferon, immunoglobulin production was further suppressed. However, after 4 months of therapy with interferon, pokeweed mitogen-stimulated immunoglobulin production partially returned towards the pretreatment values. Antibody to hepatitis B core antigen was less affected by interferon therapy. This altered response to interferon was not specific as it was seen in some patients with other forms of liver disease. The suppression of B cell differentiation appears to be separate from its antiviral and anti-proliferative effects.

UR - http://www.scopus.com/inward/record.url?scp=0022974928&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(86)80133-7

DO - 10.1016/S0168-8278(86)80133-7

M3 - Article

C2 - 3598159

AN - SCOPUS:0022974928

SN - 0168-8278

VL - 3

SP - S283-S289

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - SUPPL. 2

ER -

Immune effects of α-interferon in chronic liver disease

Abstract

Access to Document

Fingerprint

Cite this